TransCode Therapeutics, Inc. (RNAZ)

TransCode Therapeutics Statistics

Total Valuation

RNAZ has a market cap or net worth of $9.34 million. The enterprise value is $3.56 million.

Market Cap	9.34M
Enterprise Value	3.56M

Important Dates

The next estimated earnings date is Wednesday, May 14, 2025, before market open.

Earnings Date	May 14, 2025
Ex-Dividend Date	n/a

Share Statistics

RNAZ has 23.34 million shares outstanding.

Current Share Class	23.34M
Shares Outstanding	23.34M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+37.07%
Owned by Insiders (%)	0.15%
Owned by Institutions (%)	0.54%
Float	23.31M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	-4.62
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.56

Current Ratio	2.56
Quick Ratio	2.10
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-584.07

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-157.06%
Return on Invested Capital (ROIC)	-17,645.14%
Return on Capital Employed (ROCE)	-346.27%
Revenue Per Employee	n/a
Profits Per Employee	-$1.68M
Employee Count	10
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -97.36% in the last 52 weeks. The beta is 1.52, so RNAZ's price volatility has been higher than the market average.

Beta (5Y)	1.52
52-Week Price Change	-97.36%
50-Day Moving Average	2.34
200-Day Moving Average	9.56
Relative Strength Index (RSI)	32.12
Average Volume (20 Days)	5,029,499

Short Selling Information

The latest short interest is 2.55 million, so 10.94% of the outstanding shares have been sold short.

Short Interest	2.55M
Short Previous Month	339,770
Short % of Shares Out	10.94%
Short % of Float	10.96%
Short Ratio (days to cover)	0.17

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-15.66M
Pretax Income	-17.06M
Net Income	-16.75M
EBITDA	-15.57M
EBIT	-15.66M
Earnings Per Share (EPS)	-$47.05

Balance Sheet

The company has $5.81 million in cash and $38,291 in debt, giving a net cash position of $5.77 million or $0.25 per share.

Cash & Cash Equivalents	5.81M
Total Debt	38,291
Net Cash	5.77M
Net Cash Per Share	$0.25
Equity (Book Value)	-2.02M
Book Value Per Share	-1.96
Working Capital	4.32M

Cash Flow

In the last 12 months, operating cash flow was -$13.34 million and capital expenditures -$21,761, giving a free cash flow of -$13.36 million.

Operating Cash Flow	-13.34M
Capital Expenditures	-21,761
Free Cash Flow	-13.36M
FCF Per Share	-$0.57

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

RNAZ does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-179.46%
FCF Yield	-143.07%

Analyst Forecast

The average price target for RNAZ is $10.00, which is 2,400.00% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$10.00
Price Target Difference	2,400.00%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-58.32%

Stock Splits

The last stock split was on December 4, 2024. It was a reverse split with a ratio of 0.030303:1.

Last Split Date	Dec 4, 2024
Split Type	Reverse
Split Ratio	0.030303:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	2